DEBRA HAIN: Open Payments
NPI 1932139482 · RIVERTON, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$7,259 in 16 payments from 7 companies in 2025. Trend: 2023 $4,869 · 2024 $3,621 · 2025 $7,259
Consulting: $5,737Food & beverage: $1,208Travel & lodging: $314
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 8 | $6,423 |
| Ardelyx, Inc. | 2 | $221 |
| Amgen Inc. | 2 | $215 |
| Apellis Pharmaceuticals, Inc. | 1 | $139 |
| Novo Nordisk Inc | 1 | $120 |
| CorMedix Inc. | 1 | $107 |
| Novartis Pharmaceuticals Corporation | 1 | $35 |
Products named: TARPEYO, KRYSTEXXA, XPHOZAH 30 MG, Rivfloza, DEFENCATH, IBSRELA, Fabhalta.
Industry payments across UT — which companies pay providers there.
